美托洛尔联合稳心颗粒治疗冠心病合并心律失常的临床疗效观察

A preliminary study of the clinical effect of metoprolol combined with Wenxin granules in treatment of coronary heart disease complicated by arrhythmia

目的研讨美托洛尔联合稳心颗粒治疗冠心病合并心律失常的临床疗效。方法随机抽取2012年4月至2015年10月的冠心病合并心律失常共计102例,将所有患者随机分为两组,分别是观察组和对照组,每组患者均为51例,对照组采用传统美托洛尔进行治疗,观察组采用美托洛尔联合稳心颗粒的治疗方案,比较两组患者的治疗效果、心律失常症状改善情况以及不良反应发生率。结果观察组的治疗效果好于对照组(P<0.05),观察组的心律失常症状改善情况好于对照组(P<0.05);观察组的不良反应发生率为5.88%,对照组的不良反应发生率高达23.53%,观察组的不良反应率低于对照组(P<0.05),组间比较差异具有显著性,存在统计学意义。结论美托洛尔联合稳心颗粒治疗冠心病合并心律失常的临床疗效显著,安全性高,且不良反应发生率较低,值得临床推广。

Objective To investigate the clinical effect of metoprolol combined with Wenxin granules in the treatment of coronary heart disease complicated by arrhythmia. Methods A total of 102 patients with coronary heart disease complicated by arrhythmia who were treated from April 2012 to October 2015 were selected and randomly divided into observation group and control group, with 51 patients in each group. The patients in the control group were given metoprolol alone, and those in the observation group were given metoprolol combined with Wenxin granules. The treatment outcome, relief of the symptoms of arrhythmia, and incidence of adverse events were compared between the two groups. Results Compared with the control group, the observation group had a significantly better treatment outcome（P〈0.05） and significantly greater relief of the symptoms of arrhythmia（P〈0.05）. The observation group had a significantly lower incidence rate of adverse events than the control group（5.88% vs 23.53%, P〈0.05）. Conclusion In the treatment of coronary heart disease complicated by arrhythmia, metoprolol combined with Wenxin granules has a significant clinical effect, high safety, and low incidence of adverse events, and therefore, it holds promise for clinical application.